Medivation’s Dimebon Shines In Alzheimer’s Open-label Extension Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm recently began confirmatory Phase III; expects to file in 2010 for mild-to-moderate Alzheimer’s.
You may also be interested in...
Pfizer Finds Backup For Aricept In Medivation’s Dimebon
Medivation Alzheimer’s candidate is unique for its disease-modifying potential.
Pfizer Finds Backup For Aricept In Medivation’s Dimebon
Medivation Alzheimer’s candidate is unique for its disease-modifying potential.
Wyeth’s Pipeline Star Bapineuzumab Looks More Long Shot Than Sure Bet
Following the release of lackluster Phase II efficacy data on bapineuzumab in Alzheimer’s disease patients, talk of Wyeth as a takeover target resurfaces.